熱門資訊> 正文
GoodRx推出专注于勃起功能障碍治疗的新订阅服务
2025-06-10 22:39
- Shares of GoodRx (NASDAQ:GDRX) traded higher on Tuesday after the drug savings platform announced the launch of a new subscription service focused on treatments for erectile dysfunction (ED).
- The new service comes with an online healthcare consultation and discreet home delivery, and it starts at $18 per month, with the final fee based on the prescribed ED medication, the company noted.
- According to a new GDRX-commissioned survey, while nearly a third of U.S. men suffer from ED, less than 14% of them seek treatments due to factors such as inadequate payor coverage and social stigma.
- “Designed to meet consumers where they are and remove common barriers such as high costs, long wait times, and inconvenience, this all-in-one solution offers a fast, discreet, and affordable option for ED treatment,” the company said.
More on GoodRx Holdings
- GoodRx: Stabilizing Revenue Amid Healthy Profit Gains
- GoodRx Holdings, Inc. (GDRX) Q1 2025 Earnings Call Transcript
- GoodRx: Great Value For Patient Investors (Upgrade)
- Goodrx outlines 2025 revenue guidance of $810M-$840M with focus on pharmacy partnerships
- GoodRx Holdings Q1 2025 Earnings Preview
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。